撰文丨王聪 编辑丨王多鱼 排版丨水成文 替尔泊肽 （Tizepatide） 是 礼来公司开发的一款 葡萄糖依赖性促胰岛素多肽 （GIP） 受体和胰高血糖素 样肽-1 （GLP-1） 受体的双重激动剂 ，于2023年11月获得FDA批准作为减肥药上市 （商品名 Zepbound™） ，此前还获批用于 2型糖尿病的降糖 （商品名为Mounjaro™） 。替尔泊肽是目前已上市的 效果最好的减肥药物，在临床试验中多次刷新减肥效果新纪录。 2025 年 7 月 3 日， 中国国家药监局 （NMPA） 官网公示显示， 替尔泊肽在中国获批新适应症 —— 成 人肥胖患者的中度至重度 阻塞性睡眠呼吸暂停 （OSA） ，这也是替尔泊肽在国内获批的第三个适应症， 去年，替尔泊肽先后获批用于成人 2 型糖尿病 和 肥胖症 的治疗。 此次获批新的适应症，基于替尔泊肽在 3 期临床试验 SURMOUNT-OSA 中 的积极结果，结果显示，替尔 泊肽在为期 52 周的治疗中，帮助患者平均减重 20%， 睡眠中呼吸暂停低通气次数至少减少 27次/小时， 半数以上患者已不再有 阻塞性睡眠呼吸暂停 （OSA） 相关症状。 2024年 4 月 1 ...

近一年以来，国家药监局已经批准了替尔泊肽用于治疗2型糖尿病和长期体重管理两项适应症。这项最 新获批的OSA适应症的使用，需在控制饮食和增加运动基础上进行。 接受替尔泊肽治疗的成人患者平均减重20%，睡眠中每小时呼吸暂停低通气次数至少减少27次。在接受 替尔泊肽治疗一年后，半数以上患者已不再有OSA相关症状。 7月3日，礼来宣布GLP-1类减重药替尔泊肽注射液（商品名：穆峰达）已获得中国国家药品监督管理局 （NMPA）批准，用于治疗成人肥胖患者的中度至重度阻塞性睡眠呼吸暂停（OSA）。该药物也是全球 首个且目前唯一用于治疗OSA的处方药。 OSA还与各种不良心血管疾病事件（CVD）的发生密切相关。去年发布的一份《心血管疾病患者阻塞 性呼吸睡眠暂停评估与管理专家共识（2024 版）》为我国CVD患者中OSA的评估和管理提供规范性指 导。 然而，由于患者对OSA疾病严重性认识不足，目前患者就诊率偏低，面临着严重的健康风险。 去年12月，美国FDA已经批准了替尔泊肽OSA适应症。随着该适应症在全球更多国家获批，将使礼来在 激烈的减重药市场竞争中更具优势。 礼来临床数据显示，接受替尔泊肽治疗的成人患者平均减重20%，睡 ...

Core Viewpoint - The article discusses the alarming connection between climate change and the increase in obstructive sleep apnea (OSA), highlighting that rising temperatures can exacerbate this common sleep disorder, affecting both health and economic productivity [1][5][9]. Group 1: Health Implications - Obstructive sleep apnea affects over 25 million adults in the U.S., characterized by repeated breathing interruptions during sleep due to relaxed throat muscles [1][2]. - Increased environmental temperatures are linked to a 45% higher probability of experiencing OSA on certain nights [1][2]. - Untreated or severe OSA can lead to serious health issues, including dementia, Parkinson's disease, hypertension, cardiovascular diseases, anxiety, and depression, potentially shortening lifespan [5][6]. Group 2: Economic Impact - The study estimates that the rise in OSA prevalence due to global warming will result in a loss of 30 billion USD in productivity and 68 billion USD in health deterioration costs globally [1][7]. - In 2023, the increase in OSA cases led to an additional 25 million days of absenteeism across 29 countries, translating to significant economic losses [7][8]. Group 3: Research Findings - The research analyzed sleep data from 116,620 participants across 29 countries over three and a half years, using FDA-approved monitoring devices to establish the link between daily environmental temperatures and OSA [2][3]. - The study warns that the sample may underestimate the health and economic burdens, as it primarily includes participants from developed countries with air conditioning, leaving low-income groups underrepresented [8]. Group 4: Future Projections - With global average temperatures expected to rise by 2.1°C to 3.4°C, the negative impacts of high temperatures on health are likely to worsen [9][10]. - Without effective policy measures to combat global warming, the burden of OSA could double by 2100 due to rising temperatures [10].

Nyxoah (NYXH) Q1 2025 Earnings Call May 14, 2025 08:00 AM ET Speaker0 Good day and thank you for standing by. Welcome to the Nixoa First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Pearson Dennis, Investor Relations Associate. Please go ...

Mineralys Therapeutics (MLYS) Q1 2025 Earnings Call May 12, 2025 04:30 PM ET Company Participants Dan Ferry - Managing DirectorJon Congleton - CEODavid Rodman - Chief Medical OfficerAdam Levy - CFOMichael Difiore - Managing DirectorSeamus Fernandez - Senior Managing DirectorAlice Nettleton - VP - US Pharmaceutical & Biotechnology Equity ResearchJayed Momin - Biopharma Equity Research AssociateSadia Rahman - Vice President, Biopharma Equity Research Conference Call Participants Richard Law - AnalystRami Katk ...

Nyxoah SA (NASDAQ:NYXH) Q4 2024 Earnings Conference Call March 13, 2025 8:00 AM ET Company Participants John Landry - Chief Financial Officer Olivier Taelman - CEO Conference Call Participants Adam Maeder - Piper Sandler Jon Block - Stifel Matthew Park - Cantor Fitzgerald Suraj Kalia - Oppenheimer & Co. David Rescott - Baird Paige Chamberlain - Wolfe Research Operator Hello, and welcome to Nyxoah Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After th ...